Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Structure-Based Drug Design and Development of Novel Synthetic Compounds with Anti-Viral Property against SARS-COV-2

Author(s): Reshma Tendulkar*, Aasma Chouhan, Avika Gupta, Aaliya Chaudhary, Chandani Dubey and Sushil Shukla

Volume 19, Issue 4, 2022

Published on: 18 April, 2022

Article ID: e280122200663 Pages: 53

DOI: 10.2174/1570163819666220128145724

Price: $65

Abstract

Background: The world is suffering from health and economic devastation due to the coronavirus disease-2019 (COVID-19) pandemic. Given the number of people affected and also the death rate, the virus is definitely a serious threat to humanity. The novel replication mechanism of the coronavirus is likely well understood, similar to prior studies on the severe acute respiratory syndrome (SARS-CoV-2) virus.

Objective: The antiviral activity of various compounds of the flavonoid class was checked against SARS-COVID-19 using diverse tools and software.

Methods: From the flavonoid compound class, 100 synthetic compounds with potential antiviral activity were selected and improved for screening and induced fit docking, which was reduced to 25 compounds with good docking scores and docking energies. In addition to the apparent match of the molecule with the shape of the binding pocket, a full analysis of the non-covalent interactions in the active site was assessed.

Results: Compounds nol26, fla37-fl40, an32, an39 showed a maximum docking score, which shows essential interactions for a tight bond. Now, all compounds are synthetic with beneficial drug-like properties.

Conclusion: During the docking study, an increased lipophilic interaction of compounds due to the presence of chlorine in nol26, fla37-fl40, an32, an39 was discovered. fla37-fla40 can be investigated as lead molecules against SARS-COV-2 in futuristic drug development.

Keywords: Structure, drug design, drug development, flavonoids, SARS-CoV-2, antiviral.

[1]
Forsythe IJ, Wishart DS. Exploring human metabolites using the human metabolome database Curr Protocols Bioinform 2009; 14.8.1-45..
[http://dx.doi.org/10.1002/0471250953.bi1408s25]
[2]
Wishart DS, Knox C, Guo AC, et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34(Database issue): D668-72.
[http://dx.doi.org/10.1093/nar/gkj067] [PMID: 16381955]
[3]
Jain AS, Sushma P, Dharmashekar C, et al. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2. Saudi J Biol Sci 2021; 28(1): 1040-51.
[http://dx.doi.org/10.1016/j.sjbs.2020.11.049] [PMID: 33424398]
[4]
Zhang L, Li L, Yan L, et al. Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus. J Virol 2018; 92(22): 92.
[http://dx.doi.org/10.1128/JVI.00893-18] [PMID: 30135128]
[5]
Matondo A. Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Passiflora edulis. J Complem Altern Med Res 2020; 12(3): 35-5.
[6]
Ares JJ, Outt PE, Randall JL, et al. Synthesis and biological evaluation of substituted flavones as gastroprotective agents. J Med Chem 1995; 38(25): 4937-43.
[http://dx.doi.org/10.1021/jm00025a011] [PMID: 8523407]
[7]
Singh BG, Kunwar A. In silico investigation on the binding of organoselenium compounds with target proteins of SARS-CoV-2 infection cycle. ChemRxiv Cambridge: Cambridge Open Engage 2020.
[8]
Tanoli Z, Vähä-Koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov 2021; 16(9): 977-89.
[http://dx.doi.org/10.1080/17460441.2021.1883585] [PMID: 33543671]
[9]
Zhou J, Xie G, Yan X. Volume 6 Indexes. In: Encyclopedia of Traditional Chinese Medicines - Molecular Structures, Pharmacological Activities, Natural Sources and Applications Springer,. Berlin, Heidelberg. 2011.
[http://dx.doi.org/10.1007/978-3-642-16744-7_1]
[10]
Knox C, Wilson M, Manach C, Scalbert A. HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res 2018; 2018(D1): D608-17.
[11]
Wishart DS, Knox C, Guo AC, et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36(Database issue): D901-6.
[http://dx.doi.org/10.1093/nar/gkm958] [PMID: 18048412]
[12]
David SW, Timothy J, An CG, et al. HMDB 3.0-The human metabolobe database in 2013. Nucleic Acids Res 2008; 41(D1): D801-7.
[13]
Stanzione F, Giangreco I, Cole JC. Use of molecular docking computational tools in drug discovery. Prog Med Chem 2021; 60: 273-343.
[http://dx.doi.org/10.1016/bs.pmch.2021.01.004] [PMID: 34147204]
[14]
Dawe M, Xiong Y, Clive D, et al. HMDB: A knowledge base for the human metabolome. Nucleic Acids Res 2009; 37(Database issue): D603-10.
[15]
David SW, Dan T, Craig K, Roman E. HMDB: the Human Metabolobe Database. Nucleic Acids Res 2007; 35(Database issue): D521-6.
[16]
Yang L, Gong J, Wang F, Zhang Y, et al. Synthesis and antioxidant evaluation of novel silybin analogues. J Enzyme Inhib Med Chem 2008.
[PMID: 17059172]
[17]
Fujisawa S, Atsumi T, Kadoma Y, Sakagami H. Antioxidant and prooxidant action of eugenol-related compounds and their cytotoxicity. Toxicology 2002; 177(1): 39-54.
[http://dx.doi.org/10.1016/S0300-483X(02)00194-4] [PMID: 12126794]
[18]
Bennett JP. Free radicals, oxidative stress and the origin of Parkinson’s disease. J Neurol Sci 1999; 170(2): 75-6.
[http://dx.doi.org/10.1016/S0022-510X(99)00191-4] [PMID: 10561521]
[19]
Forghieri M. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem 2009; 17(7): 2658-72.
[http://dx.doi.org/10.1016/j.bmc.2009.02.060]
[20]
Buckingham J, Munasinghe V. P In: Dictionary of Flavonoids. USA: CRC Press 2015.
[http://dx.doi.org/10.1201/b18170-20]
[21]
Bartolome AP, Villaseñor IM, Yang WC. Bidens pilosa L. (Asteraceae): Botanical properties, traditional uses, phytochemistry, and pharmacology. Evid Based Complement Alternat Med 2013; 2013,340215.
[http://dx.doi.org/10.1155/2013/340215] [PMID: 23935661]
[22]
Thomas EJ. Science of Synthesis Hetarenes and Related Ring Systems. Newyork: Thieme Verlagsgruppe 2003.
[23]
Zhou J. Volume 2 Isolated Compounds (DG) Encyclopedia of Traditional Chinese Medicines-Molecular Structures Pharmacological Activities Natural Sources and Applications. Berlin, Heidelberg: Springer 2011.
[24]
Jung-Cheng Y, Chun-Jung L, Bing-Yuan Y, Yin-Long Y, Teng-Hu C. RTLIO: Real-time LiDAR-inertial odometry and mapping for UAVs. Sensors 2021; 21(12): 3955.
[25]
Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Curr Opin Chem Biol 2002; 6(4): 439-46.
[http://dx.doi.org/10.1016/S1367-5931(02)00339-3] [PMID: 12133718]
[26]
Carlson HA, McCammon JA. Accommodating protein flexibility in computational drug design. Mol Pharmacol 2000; 57(2): 213-8.
[PMID: 10648630]
[27]
Bohacek RS, McMartin C. Modern computational chemistry and drug discovery: structure generating programs. Curr Opin Chem Biol 1997; 1(2): 157-61.
[http://dx.doi.org/10.1016/S1367-5931(97)80004-X] [PMID: 9667851]
[28]
Carlson H, McCammon J. Method for including the dynamic fluctuations of a protein in computer-aided drug design. J Phys Chem A 1999; 10213-9.
[http://dx.doi.org/10.1021/jp991997z]
[29]
Joseph-McCarthy D. Computational approaches to structure-based ligand design. Pharmacol Ther 1999; 84(2): 179-91.
[http://dx.doi.org/10.1016/S0163-7258(99)00031-5] [PMID: 10596905]
[30]
Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des 2002; 16(3): 151-66.
[http://dx.doi.org/10.1023/A:1020155510718] [PMID: 12363215]
[31]
Verlinde CL, Hol WG. Structure-based drug design: Progress, results and challenges. Structure 1994; 2(7): 577-87.
[http://dx.doi.org/10.1016/S0969-2126(00)00060-5] [PMID: 7922037]
[32]
Antel J. Integration of combinatorial chemistry and structure-based drug design Curr Opin Drug Discov Dev. 1999; 224-33.
[33]
Pervushin K, Riek R, Wider G, Wüthrich K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc Natl Acad Sci USA 1997; 94(23): 12366-71.
[http://dx.doi.org/10.1073/pnas.94.23.12366] [PMID: 9356455]
[34]
Bailey-Kellogg C, Widge A, Kelley JJ, Berardi MJ, Bushweller JH, Donald BR. The NOESY jigsaw: Automated protein secondary structure and main-chain assignment from sparse, unassigned NMR data. J Comput Biol 2000; 7(3-4): 537-58.
[http://dx.doi.org/10.1089/106652700750050934] [PMID: 11108478]
[35]
Oezguen N, Adamian L, Xu Y, Rajarathnam K, Braun W. Automated assignment and 3D structure calculations using combinations of 2D homonuclear and 3D heteronuclear NOESY spectra. J Biomol NMR 2002; 249-63.
[36]
Zheng D, Huang YJ, Moseley HN, et al. Automated protein fold determination using a minimal NMR constraint strategy. Protein Sci 2003; 12(6): 1232-46.
[http://dx.doi.org/10.1110/ps.0300203] [PMID: 12761394]
[37]
Mountain V. Astex, structural genomix, and syrrx. I can see clearly now: Structural biology and drug discovery. Chem Biol 2003; 10(2): 95-8.
[38]
Dorsey BD, Levin RB, McDaniel SL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37(21): 3443-51.
[http://dx.doi.org/10.1021/jm00047a001] [PMID: 7932573]
[39]
Erickson J, Neidhart DJ, VanDrie J, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249(4968): 527-33.
[http://dx.doi.org/10.1126/science.2200122] [PMID: 2200122]
[40]
Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248(4953): 358-61.
[http://dx.doi.org/10.1126/science.2183354] [PMID: 2183354]
[41]
Shaji D. Molecular docking studies of human MCT8 protein with soy isoflavones in Allan-Herndon-Dudley syndrome (AHDS). J Pharm Anal 2018; 8(5): 318-23.
[http://dx.doi.org/10.1016/j.jpha.2018.07.001] [PMID: 30345146]
[42]
Huang J, Song W, Huang H, Sun Q. Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: From mechanistic studies to clinical trials for COVID-19. J Clin Med 2020; 9(4): 1131.
[http://dx.doi.org/10.3390/jcm9041131] [PMID: 32326602]
[43]
Guarino LA, Bhardwaj K, Dong W, Sun J, Holzenburg A, Kao C. Mutational analysis of the SARS virus Nsp15 endoribonuclease: Identification of residues affecting hexamer formation. J Mol Biol 2005; 353(5): 1106-17.
[http://dx.doi.org/10.1016/j.jmb.2005.09.007] [PMID: 16216269]
[44]
Kim Y, Jedrzejczak R. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. bioRixv 2020; 1-18..

Rights & Permissions Print Cite
Article Metrics
32
2
© 2024 Bentham Science Publishers | Privacy Policy